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COMMENTARY
Need for streamlined use of DPP-4 
inhibitors in the treatment of type 2 diabetes
Cristiana Vitale1*, Giuseppe M. C. Rosano1,2 and Krishna Prasad3
Abstract 
Regulatory agencies request an assessment of cardiovascular safety for all “new” oral anti-diabetic drugs in order to 
avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors have emerged as a new 
therapeutic alternative for the treatment of type 2 diabetes mellitus, but the several large post-marketing clinical trials 
have shown only a modest effect in glycaemic control and, more importantly, a neutral effect on total and cardio-
vascular events. Conversely a recent trial with empagliflozin, a sodium-glucose co-transporter 2 inhibitor, has shown 
significant effect on overall and cardiovascular mortality. Although glycaemic control is an important aspect of diabe-
tes management, the results of the EMPA-REG outcome trial suggest that it is possible to develop anti-diabetic drugs 
that may exert an overall beneficial effect beyond the mere improvement of glycaemic control. While the regulatory 
hurdles should not be increased, there is the need for evaluation of the net clinical impact and cost effectiveness of 
all anti-diabetic agents. Therefore, a better collaboration among all stakeholders is needed in order to develop studies 
with endpoints that will be both clinically meaningful including appropriate follow-up, and economically relevant in 
patients with type 2 diabetes mellitus.
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Background
After the rosiglitazone saga, the main regulatory agencies 
(European Medicines Agencies, Food and Drug Adminis-
tration) have requested an assessment of cardiovascular 
safety for all “new” oral anti-diabetic drugs (OADs). This 
was in order to avoid a situation that the supposed ben-
efits, inferred from their effect on the surrogate endpoint 
of glycated haemoglobin (HbA1c), would not have been 
outweighed by negative effects on cardiovascular events. 
Dipeptidyl peptidase 4 inhibitors (DPP4i) have emerged 
as a new therapeutic alternative for the treatment of type 
2 diabetes mellitus (T2DM). Several large post-mar-
keting clinical trials have been now completed with the 
new DPP4i overall involving more than 36,000 T2DM 
patients at increased cardiovascular risk [1–5] show-
ing a neutral effect of this new class on hard outcomes. 
The SAVOR TIMI-53, the EXAMINE and the VIVIDD 
studies raised initial doubts on the cardiovascular safety 
of DPP4i [1, 2, 5] related to the increased occurrence of 
heart failure (HF) [4–6]. Reassuringly, the recent TECOS 
study [3] showed that addition of sitagliptin to usual care 
did not affect the cardiovascular composite endpoints or 
the rates of hospitalization for HF. However, DPP4i differ 
from each other in their chemical structure and conse-
quently their off target properties and this may influence 
their biological actions and therefore the overall clinical 
effect.
Discussion
Glycaemic control is an important aspect of manag-
ing diabetes and reducing microvascular complications. 
However, one of the main aims of treatment of T2DM, 
would be to reduce events and cardiovascular risk in an 
effective and safe way. With several DPP4i authorised 
thus far and others undergoing extensive development 
programmes, one may wonder if there is sufficient cer-
tainty that their effect on glycaemic control translates 
Open Access
Cardiovascular Diabetology
*Correspondence:  cristiana.vitale@gmail.com 
1 Centre for Clinical & Basic Research, IRCCS San Raffaele Pisana, via della 
Pisana, 235, 00163 Rome, Italy
Full list of author information is available at the end of the article
Page 2 of 3Vitale et al. Cardiovasc Diabetol  (2016) 15:55 
into a sustained clinical benefit. In the post-marketing 
studies the comparative glucose lowering effect of the 
tested DPP4i to placebo was pretty small and no effect on 
hard end-points was observed [3].
It could be argued that treatment duration and study 
populations might have influenced the lack of benefits 
of DPP4i [7]. However, should a longer study duration or 
a different/larger population be needed to show a ben-
eficial effect, by corollary, the magnitude of this effect 
would have been necessarily small and may be intangible. 
A combined analysis of the studies available with these 
drugs so far supports this thought given the size of the 
populations studied.
The direct comparisons with active glucose lower-
ing comparators in drug-naive patients have demon-
strated that DPP4i exert slightly less pronounced HbA1c 
reduction than metformin, suggesting a smaller effect 
on glycaemia, than the three oldest classes (insulin, the 
sulfonylureas, and the biguanides) in addition to higher 
costs that do not justify a widespread use [8].
The results of the large post-marketing trials with 
DPP4i highlight that this class of glucose lowering drugs 
provide limited beneficial effect in patients with T2DM 
and, have not provided an answer to the clinical need for 
OADs that are safe and potentially reduce cardiovascular 
complications. Therefore, approaches other than HbA1c 
lowering alone may be necessary in order to reduce 
cardiovascular events including total mortality and 
HF in these patients. This is especially true in the light 
of the recent results of the EMPA-REG outcome trial 
with empagliflozin belonging to another class of OADs, 
sodium-glucose co-transporter 2 inhibitors (STGL2i), 
that showed that, in 7020 patients with T2DM at high 
cardiovascular risk, the addition of empagliflozin to 
standard care significantly reduced the occurrence of car-
diovascular outcomes, including HF in addition to reach-
ing a target HbA1c of 7.8 % [9]. The results of this study 
suggest that this newer drug may exert an overall benefi-
cial effect beyond the mere improvement of glycaemic 
control. This may be mediated through effect on lowering 
blood pressure and reduction in fluid overload or other 
as yet unidentified mechanisms, but more data form oth-
ers in the class are required for confirmation. The mag-
nitude of these results sets the bar for the development 
of future treatments for diabetes and makes preferential 
use of drugs such as DPP4i difficult to be justifiable in the 
absence of a meaningful clinical benefit, particularly in 
the context of wide use in all diabetic patients.
From a regulatory perspective, the glucose lower-
ing effect of OADs is usually studied against placebo as 
add on often in combination with metformin in stud-
ies conducted for licensing purposes. An important 
question that might arise is: should there be a require-
ment for demonstration of added benefit over existing 
treatments and, if so, against which comparator? In this 
context, setting the regulatory bar unduly high might act 
as a deterrent for further innovation and drug develop-
ment. Regulatory agencies are bound by their remit to 
not include cost considerations in their deliberations 
for authorisation. However, cost of treatments is a soci-
etal concern and will be a part of the Health Technology 
Assessment evaluation. In our view, while the regulatory 
hurdles should not be increased, there is the need for 
evaluation of clinical impact and added value including 
cost effectiveness of these agents where large datasets 
suggest a limited benefit. This may imply encouraging 
conduct of comparative benefit trials that include cost 
benefit evaluation.
DPP4i have had a surprisingly high uptake in the oral 
anti-diabetic market worldwide with an enthusiasm that 
can only be explained by marketing. In a period in which 
the costs to the National Health Services are increas-
ing, we have to ask ourselves how long can we afford to 
pay for a small metabolic effect of newer drugs, such as 
DPP4i, whose annual cost is around £600.00/patient/year 
and the cost of treating diabetics is incremental annually 
[10]. New drugs are always needed for a patient-centred 
approach aimed to achieve a better control of glycaemia 
and reduce the risk of negative outcomes but the price of 
the new drugs should be related to their clinical benefit 
ensuring a cost-effective use of the medications.
Conclusions
With increasing population of diabetics worldwide the 
cost of treating this disease is escalating and all health 
authorities are compelled to bring cost–effectiveness to 
the fore. Therefore, it will be important to consider what 
requires to be focus of introducing newer treatments for 
T2DM and whether a refocus of the objectives of large 
trials for newer class of treatment is necessary. A further 
point that needs consideration is how do we define ben-
efits of newer class of agents such as the DDP4i that have 
only modest effect on glycaemic control and no effect on 
hard clinical end points.
Therefore, a better collaboration among all stakehold-
ers is needed in order to develop studies with endpoints 
that will be both clinically meaningful and economically 
relevant in order to justify the increased costs of newer 
drugs that can be of benefit for patients with T2DM.
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